What is ROIV's P/E ratio?

ROIVANT SCIENCES LTD (ROIV) currently trades at a P/E ratio of 76.62.

ROIVANT SCIENCES LTD reports a Return on Equity (ROE) of -6.62%.

What is ROIV's dividend yield?

ROIVANT SCIENCES LTD offers a dividend yield of 0.00%.

What is ROIV's Deepscope Quality Score?

Deepscope rates ROIV's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ROIV?

Deepscope's AI Timing Score for ROIV is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ROIV belong to?

ROIVANT SCIENCES LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Cổ phiếu ROIV (NASDAQ) | ROIVANT SCIENCES LTD

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

ROIV

ROIVANT SCIENCES LTD

US:NASDAQ STOCK Healthcare >> Biotechnology News 92

USD 28.58

-0.95 (-3.22%) Day Change

Watchlist Portfolio Compare Chart

76.62

P/E

0.00

D/E

-6.6%

ROE

-5.2%

ROA

0.00%

Div Yield

-0.27

PEG

ROIVANT SCIENCES LTD
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 28.58 Price -0.95 (-3.22%) Day Change	NEWS SCORE: 92

ROIV Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	92
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	28.58
PBV / Sector	4.39 / 4.63
Earning Per Share	-0.43

PE / Sector	76.62 / 17.43
PEG or PE/Growth / Sector	-0.27 / 0.53
Average 1M Daily Value	189.44 M GREAT
Average 1W Daily Value	122.89 M GREAT

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-3,629.19 / 449.48
NPM Average (%) / Sector	1,468.20 / -1,506.49
NPM Change Average (%) / Sector	-35.59 / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-5.23 / 30.58
ROA Average (%) / Sector	2.40 / -347.17
ROA Change Average (%) / Sector	-94.14 / 5,125.52
ROE (%) / Sector	-6.62 / -3.58
ROE Average (%) / Sector	-6.14 / 40.65
ROE Change Average (%) / Sector	-69.39 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

Chi tiết đăng ký

Analyze Date	2026-06-06 09:09:01
Symbol	ROIV
Name	ROIVANT SCIENCES LTD
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	719.27 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	23,215.17 / 8,857.28

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 50 Broadway, London, United Kingdom, SW1H 0DB

Phone: 44 20 7400 3347

Website: https://roivant.com

Employees: 721

Sector: Healthcare >> Biotechnology

Description: Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.